Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Consensus Target Price of $20.00 According to Brokerages

Keros Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Keros Therapeutics a consensus “Moderate Buy” rating, with an average 12-month price target of $20.00. Ratings are mixed among seven firms: four recommend buying, two hold, and one sell.
  • Keros reported quarterly EPS of $0.70, beating the consensus estimate of a $0.96 loss, and revenue of $40.01 million versus $14.76 million expected.
  • The company authorized a $5 million share repurchase, covering up to 2.3% of outstanding shares; the stock was reported up 12.8%.
  • Five stocks we like better than Keros Therapeutics.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.00.

A number of research firms have weighed in on KROS. Zacks Research raised shares of Keros Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 9th. Leerink Partners decreased their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, August 4th. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Wall Street Zen upgraded shares of Keros Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, November 9th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Keros Therapeutics in a report on Tuesday, November 10th.

Check Out Our Latest Analysis on Keros Therapeutics

Keros Therapeutics Stock Up 12.8%

Shares of NASDAQ:KROS opened at $11.31 on Wednesday. Keros Therapeutics has a twelve month low of $8.98 and a twelve month high of $22.55. The stock's 50 day moving average is $11.01 and its 200-day moving average is $11.62. The firm has a market capitalization of $221.90 million, a price-to-earnings ratio of -4.01 and a beta of 1.13.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $1.66. The business had revenue of $40.01 million during the quarter, compared to the consensus estimate of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.85%. Equities research analysts anticipate that Keros Therapeutics will post -3.73 earnings per share for the current fiscal year.

Keros Therapeutics declared that its board has initiated a share repurchase plan on Wednesday, September 9th that authorizes the company to repurchase $5 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2.3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. Man Group plc bought a new position in Keros Therapeutics during the 2nd quarter valued at $1,664,000. Nantahala Capital Management LLC purchased a new position in Keros Therapeutics during the 2nd quarter worth $15,091,483. Empowered Funds LLC bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth $1,521,000. ADAR1 Capital Management LLC bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth $2,641,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Keros Therapeutics by 453.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company's stock worth $3,547,000 after acquiring an additional 263,347 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-β) protein family. Its research has centered on disorders involving blood-cell production and muscle function. The company's pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions.

See Also

Analyst Recommendations for Keros Therapeutics (NASDAQ:KROS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Keros Therapeutics Right Now?

Before you consider Keros Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.

While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines